AS
Arun Suresh Chandavarkar
About Arun Suresh Chandavarkar
Data last updated:
Arun Suresh Chandavarkar is a Director at Biocon Biologics Limited (since 2016), Director at Biocon Research Limited (since 2008) and Director at Mynvax Private Limited (since 2021), and holds 2 more current directorships. The companies operate in Pharma and Life Sciences. The 3 current companies with reported revenue have a combined latest revenue of ₹10,395 Cr; the largest is Biocon Biologics Limited at ₹10,144 Cr (FY 2025). Earlier, Arun Suresh Chandavarkar was a Managing Director at Biocon Limited (2014–2019) and Director at Biocon Pharma Limited (2014–2020) and 1 more.
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Biocon Biologics Limited U24119KA2016PLC093936 | Director | 08 Jun 2016 | 2016 | ₹10,144 Cr (FY 2025) | Active |
| Biocon Research Limited U73100KA2008PLC046583 | Director | 28 May 2008 | 2008 | ₹247 Cr (FY 2019) | Active |
 Mynvax Private Limited U73200KA2017PTC102838 | Director | 01 Jan 2021 | 2017 | ₹3.56 Cr (FY 2025) | Active |
 Biocon Limited L24234KA1978PLC003417 | Director | 01 Aug 2026 | 1978 | Active | |
| Syngene International Limited L85110KA1993PLC014937 | Director | 29 Jul 2026 | 1993 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Biocon Limited L24234KA1978PLC003417 | Managing Director | 24 Apr 2014 | 1978 | ₹16,470 Cr (FY 2025) | Active |
| Biocon Pharma Limited U24232KA2014PLC077036 | Director | 31 Oct 2014 | 2014 | ₹982 Cr (FY 2025) | Active |
| Biocon Biopharmaceuticals Limited U24231KA2002PLC030643 | Nominee Director | 22 Mar 2007 | 2002 | Amalgamated |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Arun Suresh Chandavarkar
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Arun Suresh Chandavarkar
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arun Suresh Chandavarkar
Arun Suresh Chandavarkar currently holds 5 directorships: Biocon Biologics Limited (Director, since 08 Jun 2016, revenue ₹10,144 Cr (FY 2025)); Biocon Research Limited (Director, since 28 May 2008, revenue ₹247 Cr (FY 2019)); Mynvax Private Limited (Director, since 01 Jan 2021, revenue ₹3.56 Cr (FY 2025)); Biocon Limited (Director, since 01 Aug 2026); Syngene International Limited (Director, since 29 Jul 2026).
Arun Suresh Chandavarkar was first appointed on 22 Mar 2007 as Nominee Director at Biocon Biopharmaceuticals Limited. The most recent appointment on record is 01 Aug 2026 at Biocon Limited.
The 3 current companies of Arun Suresh Chandavarkar that report revenue have a combined latest revenue of ₹10,395 Cr: Biocon Biologics Limited ₹10,144 Cr (FY 2025); Biocon Research Limited ₹247 Cr (FY 2019); Mynvax Private Limited ₹3.56 Cr (FY 2025).
Arun Suresh Chandavarkar held 3 earlier board appointments: Biocon Limited (Managing Director, 24 Apr 2014 to 30 Nov 2019); Biocon Pharma Limited (Director, 31 Oct 2014 to 23 Jan 2020); Biocon Biopharmaceuticals Limited (Nominee Director, from 22 Mar 2007).
The current boards of Arun Suresh Chandavarkar's companies include Akhilesh Nand (Biocon Biologics Limited), Bobby Kanubhai Parikh (Biocon Biologics Limited), Daniel Mark Bradbury (Biocon Biologics Limited), Kiran Mazumdar Shaw (Biocon Biologics Limited), Mr. Kedar Upadhye (Biocon Biologics Limited), Nivruti Rai (Biocon Biologics Limited), among others.